Treatments for EGFR Mutation-Positive (M+) NSCLC Patients - A Network Meta-Analysis (NMA) by Mutation Type
Value Health
.
2014 Nov;17(7):A615.
doi: 10.1016/j.jval.2014.08.2166.
Epub 2014 Oct 26.
Authors
S Popat
1
,
J Lungershausen
2
,
I Griebsch
2
,
A Marten
3
,
Y L Wu
4
Affiliations
1
Royal Marsden Hospital, London, UK.
2
Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany.
3
Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
4
Guangdong Lung Cancer Institute, Guangzhou, China.
PMID:
27202154
DOI:
10.1016/j.jval.2014.08.2166
No abstract available